Stockscreener 앱 받기
0.2698
2.95%
-0.0082
시간 외 거래:
.27
0.0002
+0.07%
전일 마감가:
$0.278
열려 있는:
$0.278
하루 거래량:
465.54K
Relative Volume:
0.22
시가총액:
$4.15M
수익:
$4.71M
순이익/손실:
$-11.79M
주가수익비율:
-0.0806
EPS:
-3.3492
순현금흐름:
$-9.72M
1주 성능:
+6.22%
1개월 성능:
-3.68%
6개월 성능:
-76.12%
1년 성능:
-87.03%
1일 변동 폭
$0.262
$0.278
1주일 범위
$0.2461
$0.285
52주 변동 폭
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.2698 | 4.15M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences Slips 3.94% as Stock Tests Key Support at $0.23New Listing Stocks - newsline.com
ENSC Q1 2026 Earnings: Narrowing Losses Signal Progress Amid Market VolatilityEarnings Acceleration Picks - The League of Women Voters of Texas
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences Files for Sale of 1.3 Million Shares - Moomoo
Ensysce Biosciences (NASDAQ: ENSC) registers up to 1.3M shares for resale - Stock Titan
ENSC Q1 2026 Earnings: Narrower-Than-Expected Loss Despite No RevenueEarnings Whisper Number - The Legal Advocate
ENSC Q1 2026 Earnings: Narrower-than-expected loss boosts sharesMargin Guidance - newsline.com
Ensysce Biosciences (ENSC) Drops 3% as Stock Nears Support at $0.28MA Crossover - The Legal Advocate
Ensysce Biosciences (ENSC) Declines Further, Tests Key Support Near $0.29Diamond Pattern - Newser
Ensysce Faces New Nasdaq Issue as Deadline Nears - Bez Kabli
ENSC Q1 2026 Earnings: Narrower-than-expected Net Loss as EPS Beats EstimatesSegment Revenue Breakdown - The Legal Advocate
Ensysce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Compliance Update - Minichart
Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule - Investing.com
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Ensysce Biosciences (NASDAQ: ENSC) warned on Nasdaq equity listing rule - Stock Titan
Ensysce Biosciences : Corporate Overview - marketscreener.com
ENSC Advancing Testing and Expanding Potential - Yahoo Finance
Ensysce Biosciences (ENSC) Rallies +0.54% as Bulls Target $0.29 2026-05-18OBV Divergence - Newser
Ensysce Biosciences (ENSC) Crushes Q1 2026 Estimates — EPS $-0.52 Tops ViewsCFO Commentary Report - The Legal Advocate
Press Releases about Ensysce Biosciences, Inc.Common Stock - The Chronicle-Journal
Ensysce Biosciences, Inc.Common Stock (Nasdaq:ENSC) Stock Quote - The Chronicle-Journal
Ensysce Biosciences (ENSC) price target decreased by 34.79% to 16.78 - MSN
Ensysce Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ensysce biosciences launches formal review of strategic alternativesSEC filing - marketscreener.com
Ensysce Biosciences Launches Formal Review Of Strategic AlternativesSEC Filing - TradingView
Ensysce Biosciences : Earnings Release Q1 2026 - marketscreener.com
ENSC: Clinical milestones and new financing highlight Q1 2026 amid ongoing R&D-driven losses - TradingView
Wider Q1 loss leaves Ensysce (NASDAQ: ENSC) with limited cash runway - Stock Titan
Ensysce Biosciences (ENSC) posts Q1 2026 loss, cash squeeze and strategic review - Stock Titan
This biotech is testing an opioid designed to limit overdose risk - Stock Titan
ENSC Q1'26 Earnings: EPS estimate is (0.73) USD - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Nasdaq most active stocks: - MSN
TradingKey - TradingKey
Ensysce receives Taiwan patent for overdose protection technology - Investing.com UK
Ensysce receives Taiwan patent for overdose protection technology By Investing.com - Investing.com South Africa
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Corsicana Daily Sun
Opioid overdose-protection tech MPAR gets Taiwan patent to 2042 - Stock Titan
Sold 🍀🤞🏻 - Moomoo
$Ensysce Biosciences (ENSC.US)$ something in the milk aint clean…LG - Moomoo
MSN Money - MSN
Ensysce Biosciences Inc expected to post a loss of 73 cents a shareEarnings Preview - TradingView
Why are smart money investors paying attention to Ensysce Biosciences (ENSC)? (Tumbles Hard) 2026-05-08Wall Street Picks - Newser
Ensysce CEO outlines abuse-resistant opioid approach in Amsterdam - Stock Titan
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam - Corsicana Daily Sun
ENSC Ensysce Biosciences reports narrower Q4 2025 loss than estimates, shares climb after earnings release.Senior Analyst Forecasts - newser.com
ENSC - Finviz
Ensysce Biosciences (ENSC) Sector Trends | Q4 2025: EPS Beats ForecastsCommunity Chart Signals - UBND thành phố Hải Phòng
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):